Détail de l'auteur
Documents disponibles écrits par cet auteur
trié(s) par (Pertinence décroissant(e), Titre croissant(e)) Affiner la rechercheArticle
P. Giraud ; E. Blais ; A. Jouinot ; J. Wasserman ; F. Ménégaux ; L. Leenhardt ; P. Maingon ; J.-M. Simon |Objectif de l’étude : La radiothérapie est souvent d’indication tardive pour les carcinomes différenciés de la thyroïde en rechute réfractaire à l'iode. L’objectif de cette étude était de décrire l’efficacité et la toxicité de la radiothérapie c[...]Article
P. Giraud ; Cyrus Chargari ; P. Maingon ; Jean-Michel Hannoun-Lévi ; D. Azria ; É. Monpetit ; M.-A. Mahé ; I. Barillot ; A. Lisbona ; J.-J. Mazeron |The purpose of the first two editions of the guidelines for external radiotherapy procedures, published in 2007 and 2016 respectively, was to issue recommendations aimed at optimising, harmonising and standardising practices. The purpose of this[...]Article
E. Rio ; F. Mornex ; P. Maingon ; D. Peiffert ; L. Parent |We present the update of the recommendations of the French society of oncological radiotherapy on hepatic tumours. Recent technological progress led to develop the concept of focused liver radiation therapy. We must distinguish primary and secon[...]Article
C. Evin ; Y. Eude ; J. Jacob ; C. Jenny ; R. Bourdais ; B. Mathon ; C.A. Valery ; E. Clausse ; J.-M. Simon ; P. Maingon ; L. Feuvret |Purpose : The aim of the present retrospective study was to report outcomes after hypofractionated stereotactic radiotherapy (HSRT) for resected brain metastases (BM). Patients and methods : We reviewed results of patients with resected BM tre[...]Article
C. Fenioux ; I. Troussier ; A. Amelot ; P.Y. Borius ; C.H. Canova ; E. Blais ; J.-J. Mazeron ; P. Maingon ; C.A. Valery |Purpose Despite significant advances that have been made in management of metastatic melanoma with immune checkpoint therapy, optimal timing of combination immune checkpoint therapy and stereotactic radiosurgery is unknown. We have reported tox[...]Article
This article reviews the various treatment options, by primary or postoperative external radiotherapy and by brachytherapy for the p16-negative oropharyngeal squamous cell carcinoma. Dose levels, fractionation and association with systemic treat[...]Article
Radiotherapy alone or in association with systemic treatment plays a major role in the treatment of head and neck tumours, either as a primary treatment or as a postoperative modality. The management of these tumours is multidisciplinary, requir[...]Article
E. Mesny ; J. Jacob ; F. Culot ; V. Calugaru ; C. Jenny ; B. Fonti ; R. Bourdais ; F. Courtault-Deslandes ; G. Boulle ; N. Meillan ; J.-M. Simon ; P. Maingon ; L. Feuvret |Purpose Management of inter- and intra-fraction movements of target volumes and organs at risk (OARs) during radiotherapy is essential. While there is little OAR or target volume movement, the movements and orientation of the eyes can be signifi[...]Article
J. Biau ; Yoann Pointreau ; P. Blanchard ; C. Khampan ; P. Giraud ; M. Lapeyre ; P. Maingon |We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of laryngeal cancers. Intensity modulated radiotherapy is the standard of care radiotherapy for the management of laryngeal cancers. E[...]Article
P. Blanchard ; J. Biau ; F. Huguet ; S. Racadot ; C. Berthold ; S. Wong-Hee-Kam ; M.-C. Biston ; P. Maingon |Nasopharyngeal cancers are a rarity in France. Radiotherapy is the cornerstone of treatment, frequently combined with chemotherapy. The technical modality of radiotherapy is complex in this disease, which is located in the vicinity of numerous o[...]Article
P. Maingon ; V. Marchesi ; D. Azria ; J. Balosso ; É. Deutsch ; Élisabeth Cohen Jonathan-Moyal ; P. Giraud ; É. Bayart |The RadioTransNet programme launched under the auspices of French societies for radiation oncology (SFRO) and medical physics (SFPM) was approved by the French national cancer institute (INCa) in December 2018 and is dedicated to proposing a rel[...]
